190 related articles for article (PubMed ID: 32017154)
1. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
[TBL] [Abstract][Full Text] [Related]
2. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
3. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
4. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
Watthanasuntorn K; Abid H; Gnanajothy R
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567243
[TBL] [Abstract][Full Text] [Related]
5. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
Blackley S; Anderson K; Berg J
J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
[TBL] [Abstract][Full Text] [Related]
6. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
7. Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease.
Saleem S; Patel S; Ahmed A; Saleem N
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29848528
[TBL] [Abstract][Full Text] [Related]
8. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
9. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
10. Hypocalcaemia after denosumab in older people following fracture.
Chen J; Smerdely P
Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
[TBL] [Abstract][Full Text] [Related]
11. Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.
Zeng W; Swee DS
Medicine (Baltimore); 2022 Jul; 101(26):e29731. PubMed ID: 35776989
[TBL] [Abstract][Full Text] [Related]
12. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
Imatoh T; Sai K; Takeyama M; Hori K; Karayama M; Furuhashi K; Segawa K; Kimura M; Kawakami J; Saito Y
J Clin Pharm Ther; 2019 Feb; 44(1):62-68. PubMed ID: 30144112
[TBL] [Abstract][Full Text] [Related]
13. Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
Patell K; Ajay K; Al Armashi AR; Bawwab A; Ravakhah K
J Oncol Pharm Pract; 2022 Apr; 28(3):698-702. PubMed ID: 34693819
[TBL] [Abstract][Full Text] [Related]
14. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
Daga N; Joseph F
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan.
Imatoh T; Sai K; Takeyama M; Segawa K; Yamashita T; Nakashima N; Kataoka Y; Yokoi H; Hiramatsu T; Ohe K; Kimura M; Hori K; Kawakami J; Saito Y
J Clin Pharm Ther; 2019 Oct; 44(5):788-795. PubMed ID: 31282013
[TBL] [Abstract][Full Text] [Related]
16. Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis.
Shrosbree JE; Elder GJ; Eisman JA; Center JR
Intern Med J; 2018 Jun; 48(6):681-687. PubMed ID: 29363863
[TBL] [Abstract][Full Text] [Related]
17. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
18. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis.
Kanbayashi Y; Sakaguchi K; Hongo F; Ishikawa T; Tabuchi Y; Ukimura O; Takayama K; Taguchi T
Sci Rep; 2021 Jan; 11(1):978. PubMed ID: 33441770
[TBL] [Abstract][Full Text] [Related]
19. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
20. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
